Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
about
Diagnosis and management of the primary headache disorders in the emergency department settingInteractions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriersThe Neuropharmacology of Cluster Headache and other Trigeminal Autonomic CephalalgiasHigh-Resolution Genetics Identifies the Lipid Transfer Protein Sec14p as Target for Antifungal ErgolinesWhere is dihydroergotamine mesylate in the changing landscape of migraine therapy?Preventing disturbing migraine aura with lamotrigine: an open study.Indolealkylamines: biotransformations and potential drug-drug interactionsSuccessful treatment of status migrainosus after electroconvulsive therapy with dihydroergotamine.Migraine treatment throughout the lifecycle.Experimental migraine models and their relevance in migraine therapy.History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward.Migraine and stroke: current perspectives.Dihydroergotamine: role in the treatment of migraine.Adverse effects of medications commonly used in the treatment of migraine.Current and emerging treatment options for migraine and other primary headache disorders.Serotonergic agents in the management of cluster headache.Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.What happens to the old headache medicines?MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.Orally inhaled dihydroergotamine: a review.Exacerbation of SUNCT and SUNA syndromes during intravenous dihydroergotamine treatment: A case series.Headache, cerebral aneurysms, and the use of triptans and ergot derivatives.Medication overuse and chronic migraine: a critical review according to clinical pharmacology.A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine.Considerations for management of migraine symptoms in the primary care setting.Inhaled drug therapy development for the treatment of migraine.Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations.MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.Triptans: actions and reactions.AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.Advances in drug development for acute migraine.Management of vestibular migraine.Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure.The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats.Toxicological assessment of dihydroergotamine after chronic inhalation in dogs.Ergotism unresponsive to multiple therapeutic modalities, including sodium nitroprusside, resulting in limb loss.Scientific Opinion on Ergot alkaloids in food and feedSide effects associated with current and prospective antimigraine pharmacotherapies.Intravenous dihydroergotamine therapy for pediatric abdominal migraines.
P2860
Q24651176-B56BA098-9592-4FBC-9896-7969FF7F1B38Q24676273-DE5EFF3E-CF3D-48EB-A9F8-0C71D8B0131DQ26786375-BC08E8CB-E157-45E8-BF50-E9D0F0239DD4Q28554843-597FEA45-81AB-49B8-BE8E-4C909645D984Q34150104-4D825BEC-F565-4F5A-835D-6FB6C4E6E13EQ34650041-A6D1B8DD-CC74-4692-A6FC-C1FD79BF4436Q34775667-232A9294-9DDD-48E1-A20E-7F8B39EEF8BDQ36100805-168FA736-200E-4F36-AD43-5F1B3DE68404Q36153372-9302F702-8230-4EE6-B0C9-DEA1B71655E3Q36474260-271A06ED-0480-40DB-80EE-5DC075BBAC9DQ37155841-F26C2640-1694-41A4-BBE6-2FA856217B24Q37282908-7156BF57-389C-4A52-B150-063A1A6E7BEEQ37558538-BA44F6FF-25EF-4708-9293-59CCDF17597CQ37600874-3CF1D538-EC03-403B-9E4D-B20CE7322CEDQ37610198-DBA9C24D-E544-4851-ACF5-C64A77B83186Q37832687-77FFE09E-B456-49F5-99C5-E80A1C2300C8Q37996578-B4065D3A-B3E2-4601-B1EF-B40F9A20708EQ38001056-74D0DB48-8C67-452B-88D6-E514565EE898Q38031885-B7A013E2-3F2D-4A09-BB3F-DF66B676B78EQ38130336-35B77F59-A6BC-4BF3-B005-13E311D0FA6EQ38136257-24FCA2F2-CFAE-4855-A65E-94992D70418EQ38350393-5E78567F-BF7E-43B0-8CC9-EC2BBEB58F61Q38436592-C4350688-19C0-4B76-AC51-EDE926508AB1Q38509398-65644FD8-F793-449E-BBC1-E0AFDB4D8E55Q38803468-476D2EAD-4D16-446B-AA45-B02D23935034Q38808208-3D990603-F49B-4A51-8EE9-B25B9942BC28Q38896569-61835418-D315-4979-8AF2-4BAE6DB9F568Q38946597-BD6CA7F3-67CC-4710-8EE2-F90809AB1748Q39268172-D376F83A-46F1-49CB-BC11-14DD040B7A17Q39321682-6DE46EAD-9A1C-4361-A3A5-97EDA57B100FQ39366862-F5FC2785-BE94-40FB-B5AF-920313988CE2Q39527265-94F37296-DDAC-44C6-B7E0-4D3AF4CC1A71Q41765630-59FF201E-6D93-4CC6-972A-D92D45D38305Q41893414-4835F808-EB7A-4974-AB07-AA11D6699018Q42704614-045ED9C5-8038-43D2-A7A4-84C9974D15F1Q46086266-FD5454E3-4494-4D77-AD23-DBCAA80FD253Q46938220-13FD19E6-1931-4E24-87BF-D1BDB2DE2996Q47152050-71FC379E-CF1E-47C7-AC7F-94AC227DDC51Q47309054-08E3D9CC-873B-4DF4-90DB-92C16F745273Q51228012-ABBB1E18-C0A4-4D00-98B9-010A7D18CB3A
P2860
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@ast
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@en
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@nl
type
label
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@ast
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@en
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@nl
prefLabel
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@ast
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@en
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@nl
P1433
P1476
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
@en
P2093
Douglas C McCrory
P304
P356
10.1046/J.1526-4610.2003.03034.X
P577
2003-02-01T00:00:00Z